Researchers turned to an alternative marker, CD22, in an effort to expand therapeutic targets. CD22-directed CAR-T cells showed promise, achieving complete remission in about 70% of patients who ...

The CD22-directed CAR-T, which was being tested in the FIRCE-1 study as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), was halted in January, with CARGO saying it ...

Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

“Given Cargo’s progress to date and its experienced leadership team, Cargo is well-positioned to be first-to-market with an autologous CD22 CAR T-cell therapy,” Reid Huber, a partner at ...